Table 1 Summary of therapeutic clinical trials utilising DNA vaccines for prostate cancer
From: DNA vaccination for prostate cancer: key concepts and considerations
Vaccine/ targeted antigen | Phase trial/ number of patients | Delivery route | Immunological response/ clinical outcome/PSA DT | Ref |
|---|---|---|---|---|
PAP: pTVG-HP (100 μg) with rhGM-CSF (200 μg) | Phase II (NCT00849121) N = 17 | i.d | No. with tripling of T-Cell specific antibodies- Group 1: 3/8 Group 2: 6/8 | [99] |
No. with doubling of PSA DT- Group 1: 3/8 Group 2: 4/9 | ||||
PAP: pTVG-HP (100 μg, 500 μg or 1500 μg) with GM-CSF (200 μg) | Phase I/IIa (NCT00582140) N = 22 | i.d. | No. with PAP-specific IFNγ-secreting CD8+ T-cells- 3/22 | [31] |
No. with tripling of CD4+ and/or | ||||
CD8+ T-cell proliferation – 9/22 | ||||
No. with doubling of PSA DT- 7/22 | ||||
PSA: PROSTVAC with GM-CSF (100 μg) | Phase II (NCT00078585) N = 125 | s.c. | Overall survival- PROSTVAC group: 25/82 Control: 7/40 | [75] |
Median survival- PROSTVAC group: 25.1 months Control: 16.6 months | ||||
PSA: Ad/PSA (106, 107, 108pfu) | Phase I (IND #9706) N = 32 | s.c. | No. with anti-PSA T cell responses- 15/28 | [74] |
No. with increased PSA-DT- 13/28 | ||||
PSA: pVAXrcPSAv531 (rhPSA) (50–1600 μg) | Phase I (NCT00859729) N = 15 | i.d. with EP (DERMAVAX) | No. with prolongation of PSA-DT by at least 50 % during study- 4/15 | [47] |
PSMA: DOM-PSMA27 (800–3200 μg) | Phase I/II N = 30 | i.m. with or without EP | No. with detectable anti-PSMA27 CD8+ T cells response- 16/30 | [48] |
No. with doubling of PSA-DT- 14/30 |